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1,2 For example, in pulmonary arterial hypertension, the distal pulmonary arteries develop intimal and medial hypertrophy, fibrosis, inflammation, and thrombosis in situ, while the pulmonary veins are spared. 1, 2 In contrast, in pulmonary veno-occlusive disease, these pathological changes are restricted to pulmonary veins with the observed effect on pulmonary arteries considered a secondary finding. 1, 2 The aberrant structural remodeling characteristic of these pulmonary vascular diseases creates a segment of increased resistance in the cardiopulmonary circuit that ultimately leads to the hemodynamic findings consistent with pulmonary hypertension, which are discoverable clinically during invasive interrogation. These elevated filling pressures, in turn, may modulate disease progression via pressure-or flow-related compensatory remodeling in previously unaffected parts of the pulmonary vascular tree, as well as the right ventricle. Thus, while pulmonary arterial hypertension and pulmonary veno-occlusive disease are diseases of the pulmonary arteries and pulmonary veins, respectively, they are illustrative of the fact that vascular remodeling and cardiopulmonary hemodynamics serve as interrelated disease modifiers that facilitate disease progression.
While there has been considerable focus on advancing our understanding of pulmonary artery remodeling, the pulmonary venous system continues to remain an understudied contributor to the pulmonary hypertensive pathophenotype. This is somewhat surprising given the high prevalence of pulmonary hypertension due to left heart disease (PH-LHD); however, there are several putative explanations for why mechanistic studies of pulmonary venous remodeling, especially in PH-LHD, lag behind that of what has been accomplished for the arterial system. The first is that that elevated pulmonary pressures and pulmonary vascular remodeling in PH-LHD has long been considered a passive response to backward transmission of elevated filling pressures. In contrast to this viewpoint, it is more likely that exposure to high pressure is a stimulus for an active remodeling process that alters pulmonary venous structures, which is subsequently followed by pulmonary arterial remodeling. 3 In fact, while pulmonary veins are anatomically and physiologically distinct from pulmonary arteries, in pulmonary hypertension, they are capable of remodeling to resemble arterial structures and can acquire a hypertrophied muscular medial layer and elastic laminae. 4 These pathological changes, often referred to as arterialization of veins, have been reported in patients with heart failure with reduced ejection fraction. 4 A second reason underlying the relative paucity of studies on pulmonary venous remodeling in PH-LHD can be attributed to the need for a reliable identifiable marker that distinguishes the remodeled pulmonary veins from pulmonary arteries. In some instances, remodeled pulmonary veins can be identified by their position in the interlobular septa while it may not be possible to differentiate hypertrophied veins located elsewhere, especially in the periphery, from pulmonary arteries leading to their classification as "indeterminate vessels." One study suggested urokinase plasminogen activator receptor as a candidate molecular marker of pulmonary veins in PH-LHD, but went on to demonstrate that this protein was induced and eventually detectable in remodeled pulmonary arteries, as well. 4 Finally, there has been a need for comprehensive histopathologic analyses of pulmonary venous remodeling in PH-LHD coupled with clinical phenotyping data to serve as a roadmap for future studies in this area.
In this issue of Circulation, Fayyaz et al provide pathological evidence of pulmonary venous and arterial remodeling in patients with PH-LHD and demonstrate an association between the degree of vascular remodeling and pulmonary artery pressures. 5 This finding serves as foundational evidence to confirm the relationship between pressure and venous remodeling and underscores the fact that dose matters. This alone has significant goal-for-treatment implications. Through study of a combined group of patients with heart failure with preserved ejection fraction and heart failure with reduced ejection fraction, the authors make several other interesting observations with respect to pressure and pulmonary vascular remodeling in PH-LHD. Patients with heart failure with preserved ejection fraction and heart failure with reduced ejection fraction had similar left atrial dilatation and pulmonary artery systolic pressures suggesting that pulmonary venous remodeling occurred in response to a shared common property, namely elevated pressure in the pulmonary vasculature, and not due to differences in their clinical characteristics, comorbidities, or the underlying cause of heart failure. Pathological examination of the pulmonary veins and arteries revealed that pulmonary venous luminal narrowing resulting from increased venous neointimal thickening was associated with pulmonary artery medial hypertrophy. 5 This corroborates the long-term downstream effects of high-filling pressures on the pulmonary veins and exemplifies the vascular structural basis for the clinical entity of combined post-and precapillary pulmonary hypertension.
A second interesting question that this study raises is whether the described pulmonary vascular remodeling may be reversible. Invasive hemodynamic measurements in patients with PH-LHD revealed that the median pulmonary vascular resistance was 3.9 Wood Units, which was significantly lower than that measured for patients with pulmonary veno-occlusive disease (14.8 Wood Units). 5 When considered together with the absence of dense or organized fibrosis in the remodeled vessels, it is plausible to speculate that pulmonary venous remodeling may be reversible. Although longitudinal data are not available for this cohort, this phenomenon of reversibility was, however, observed in an earlier study of a subgroup of patients with heart failure with reduced ejection fraction that had serial lung biopsies available from the time of left ventricular assist device implantation and heart transplantation. Analysis of these specimens revealed at least 1 patient who had marked improvement in cardiopulmonary hemodynamics and concomitant reversal of pulmonary venous remodeling. 4 The mechanism(s) underlying pulmonary venous remodeling in PH-LHD are likely multifactorial but do include prolonged exposure of the pulmonary venous circulation to high-filling pressures. There is precedent for this and it is akin to what happens to veins in arteriovenous fistulas and saphenous vein grafts used in arterial bypass grafting surgery that are exposed to systemic pressures. Venous neointimal hyperplasia is well documented in patients with venous stenosis and failed arteriovenous fistulas, as well as saphenous vein grafts. 6, 7 Ex vivo studies that have controlled for pressure and shear stress levels have demonstrated that a human saphenous vein exposed to arterial pressure develops a neointima within 1 week. 8 While the pulmonary veins in PH-LHD are not subjected to systemic pressures, it does suggest that higher pressure is permissive for neointima formation and the initiation of venous remodeling. This concept is supported, in part, by the current study, which reported that the percent of veins that exhibited arterialization was higher in PH-LHD patients than in those with pulmonary veno-occlusive disease, where the inciting stimulus for remodeling is not driven by pressure.
The observation that pulmonary venous remodeling in PH-LHD is associated with a reduction in the diffusing capacity for carbon monoxide (DLCO) is also intriguing. The overall reduction in DLCO parallels observations made in patients with pulmonary arterial hypertension where it was reported that ≈75% of patients have some reduction in DLCO and this is associated with a higher mortality rate. 9 A 24% reduction in DLCO at baseline has been observed in patients with heart failure with preserved ejection fraction and shown to portend a worse outcome. 10, 11 In a cohort of 108 patients with pulmonary hypertension and heart failure with preserved ejection fraction, individuals with a DLCO ≤45% had a lower survival rate at 3 years (36.5% versus 87.8%, P<0.001) and a reduced DLCO was an independent predictor of mortality (Hazard Ratio=6.6; 95% confidence interval, 2.6-16.9; P<0.001). 11 In the current study, pulmonary function testing was performed in a subset of patients that had a high rate of lung disease, obstructive sleep apnea, and tobacco use. A weak correlation was found between DLCO and increased intimal thickening in pulmonary arteries and small indeterminate vessels although the exact contribution of vascular remodeling to the reduction DLCO remains unclear due to the small sample size and other contributing factors. What the aforementioned studies do highlight is that analysis of DLCO with pulmonary function testing should be considered in PH-LHD as a reduction in this biomarker is associated with poor clinical outcomes.
Historically, pulmonary hypertension in PH-LHD has been considered a consequence of volume overload and ventricular dysfunction with limited attention paid to the effects of elevated filling pressures on pulmonary venous or arterial remodeling. The analysis of pulmonary veins and arteries in PH-LHD by Fayyaz et al 5 now moves this discussion to the foreground by providing anatomic data from a large group of patients and pairing this information with clinical phenotyping. The demonstrated, clear relationship between elevated pressure and pulmonary venous remodeling, the global nature of this finding within patients, and the downstream effects on pulmonary arteries and lung function, support a cogent argument for pursuing discovery of pulmonary vein-specific therapeutic interventions. 
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